Cooke & Bieler LP Sells 22,012 Shares of Kenvue Inc. (NYSE:KVUE)

Cooke & Bieler LP lowered its position in Kenvue Inc. (NYSE:KVUE) by 1.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,578,903 shares of the company’s stock after selling 22,012 shares during the quarter. Cooke & Bieler LP owned approximately 0.08% of Kenvue worth $33,994,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Clearstead Advisors LLC acquired a new stake in Kenvue in the third quarter valued at $25,000. Planned Solutions Inc. acquired a new stake in shares of Kenvue during the 4th quarter worth about $27,000. AdvisorNet Financial Inc acquired a new stake in shares of Kenvue during the 3rd quarter worth about $28,000. Global Retirement Partners LLC acquired a new stake in shares of Kenvue during the 3rd quarter worth about $28,000. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Kenvue during the 3rd quarter worth about $28,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on KVUE shares. William Blair started coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating for the company. JPMorgan Chase & Co. cut their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. Royal Bank of Canada cut their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. The Goldman Sachs Group began coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 price target on the stock. Finally, Sanford C. Bernstein began coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $24.85.

Kenvue Price Performance

KVUE stock remained flat at $19.58 during mid-day trading on Friday. 9,506,274 shares of the company’s stock traded hands, compared to its average volume of 12,499,857. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 52-week low of $17.82 and a 52-week high of $27.80. The stock’s 50 day moving average is $19.84 and its two-hundred day moving average is $20.16.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.28 by $0.03. The firm had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. On average, analysts anticipate that Kenvue Inc. will post 1.15 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 4.09%. The ex-dividend date was Tuesday, February 13th.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.